White Paper Drafting Group Assignments

White Paper Drafting Group Assignments *Asterisks indicates a Session Chair or Panelist

Note that the Rapporteur will facilitate the overall discussion and record the final set of selected recommendations and any revisions. Key points of the White Paper drafting discussion may also be recorded.

Group 1: Applying Genomics to Daily Clinical Practice George D. Demetri, Dana-Farber Cancer Institute, Boston, MA* Sandra J. Horning, Genentech, Inc., South San Francisco, CA Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, Houston, TX Katherine L. Nathanson, University of Pennsylvania, Philadelphia, PA Lillian L. Siu, Princess Margaret Cancer Center, Toronto, Canada (rapporteur) Peter P. Yu, Hartford Health Care Cancer Institute, Hartford, CT*

Group 2: Regulation of Genetic Testing (rapporteur) Allen E. Bale, Yale University, New Haven, CT* Gideon M. Blumenthal, Food and Drug Administration, Silver Spring, MD* Girish Putcha, Palmetto GBA, Columbia, SC*

Group 3: Coverage and Reimbursement José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY* Susan M. Galbraith, AstraZeneca, Macclesfield, England* Ronald M. Kline, Centers for Medicare & Medicaid Services, Baltimore, MD * John Leite, Illumina, Inc., San Diego, CA (rapporteur) Lee N. Newcomer, United Health Group, Hopkins, MN* Michael J. Pellini, Foundation Medicine, Inc., Cambridge, MA* Sean Tunis, Center for Medical Technology Policy, Baltimore, MD

Group 4: Creating Knowledge Systems Amy P. Abernethy, Flatiron Health, New York, NY Mia Levy, Vanderbilt University, Nashville, TN Steven Joffe, University of Pennsylvania, Philadelphia, PA* (rapporteur) Louis M. Staudt, National Cancer Institute, Bethesda, MD* Zach Weinberg, Flatiron Health, New York, NY

Group 5: Germline Testing Stephen J. Chanock, National Cancer Institute, Bethesda, MD* (rapporteur) Susan M. Domchek, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA* Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA* Mark E. Robson, Memorial Sloan Kettering Cancer Center, New York, NY*

Group 6: Emerging Genomic Technologies Alberto Bardelli, University of Torino, Torino, Italy (rapporteur) Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Center, Baltimore, MD* Mark Lee, GRAIL Inc., San Francisco, CA* AmirAli Talasaz, Guardant Health, Redwood City, CA

Group 7: Accelerating Basic Research Carlos M. Caldas, Cancer Research UK Cambridge Research Institute, Cambridge, England John D. Carpten, University of Southern California Keck School of Medicine, Los Angeles, CA Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, MA * (rapporteur) Elaine R. Mardis, Washington University School of Medicine, St. Louis, MO*

Group 8: Development and Approval of New Drugs Jeffrey S. Abrams, National Cancer Institute, Rockville, MD* Julia Beaver, Food and Drug Administration, Silver Spring, MD John C. Byrd, The Ohio State University Wexner Medical Center, Columbus, OH* Barbara A. Conley, National Cancer Institute, Rockville, MD James H. Doroshow, National Cancer Institute, Bethesda, MD (rapporteur) Keith T. Flaherty, Massachusetts General Hospital, Boston, MA* Jerry S.H. Lee, Office of the Vice President, Washington, DC